Current and emerging drug treatment strategies for polycystic ovary syndrome


Helvaci N., YILDIZ O. B.

EXPERT OPINION ON PHARMACOTHERAPY, 2022 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Review
  • Publication Date: 2022
  • Doi Number: 10.1080/14656566.2022.2108702
  • Journal Name: EXPERT OPINION ON PHARMACOTHERAPY
  • Journal Indexes: Science Citation Index Expanded, Scopus, PASCAL, EMBASE, MEDLINE
  • Keywords: Antiandrogens, GLP-1, GLP-1 receptor agonists, incretin mimetics, inositol, kisspeptin-neurokinin B antagonists, oral contraceptives, PCOS, SGLT2 inhibitors, RECEPTOR AGONIST TIRZEPATIDE, COMBINED ORAL-CONTRACEPTIVES, GLUCAGON-LIKE PEPTIDE-1, SIGNIFICANT WEIGHT-LOSS, BETA-CELL FUNCTION, OBESE WOMEN, INSULIN-RESISTANCE, VITAMIN-D, INHIBITOR SITAGLIPTIN, METABOLIC PARAMETERS

Abstract

Introduction Polycystic ovary syndrome (PCOS) is a common hormonal, metabolic, and reproductive disorder with a heterogeneous phenotype. As the exact etiology of PCOS is still unclear, available pharmacotherapies are mostly directed toward alleviating symptoms and associated metabolic abnormalities. Areas covered Herein, we present an overview of the current and emerging pharmacotherapies for the management of women with PCOS who do not seek pregnancy. We performed a literature search in PubMed database up to January 2022 and reviewed papers assessing drug treatments for PCOS. We aimed to outline the most recent evidence to support treatment recommendations in these patients. Expert opinion Targets for medical treatment include hormonal, reproductive, and metabolic abnormalities in PCOS. However, none of the available pharmacological options can cover the entire spectrum of clinical manifestations observed in these patients. Considering the heterogeneity of PCOS, treatment should be individualized and adapted to specific needs of each patient. Better understanding of the molecular mechanisms underlying the pathogenesis of PCOS would help development of novel, safer, and more effective multi-targeted therapeutic strategies for the syndrome.